HIF-prolylhydroxylase inhibitors: the future for anemia treatment in patients with chronic kidney disease
- Autores: Levchenkova O.S.1, Novikov V.E.1, Vorobyova V.V.2, Kozlov S.N.1
-
Afiliações:
- Smolensk State Medical University
- St. Petersburg State University
- Edição: Volume 17, Nº 1 (2025)
- Páginas: 76-85
- Seção: Literature Reviews
- URL: https://journals.eco-vector.com/2075-3594/article/view/679287
- DOI: https://doi.org/10.18565/nephrology.2025.1.76-85
- ID: 679287
Citar
Texto integral



Resumo
Anemia is a frequent complication of chronic kidney disease (CKD) and is caused by deficiency of endogenous erythropoietin (EPO) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (HIF-PHI) represent a new class of drugs for the treatment of anemia in CKD. Along with iron preparations and erythropoiesis-stimulating agents (ESA), HIF-PHI are attempting to take their place in the correction of anemia to reduce hemotransfusion need in patients and have demonstrated as much efficacy as ESA. In contrast to the latter, HIF-PHI are oral drugs that increase endogenous EPO levels, reduce hepcidin level, and improve iron homeostasis. However, the ability of these drugs to increase the expression of a number of HIF-associated genes, not only EPO and proteins involved in iron metabolism, by stabilizing the transcription factor HIF, leads to nonselective action. The activation of angiogenesis associated with increased formation of vascular endothelial growth factor (VEGF), which may stimulate tumor growth, increase the risk of metastasis, be associated with poor prognosis, drug resistance in various types of malignancies, as well as affect the progression of polycystic kidney disease and diabetic retinopathy is of particular concern. In addition, an increased risk of thrombosis, hyperkalemia, thyroid disorders, etc. is noted. All this dictates the necessity to analyze the benefit-risk ratio when choosing HIF-PHI as antianemic agents and long-term clinical trials of this group of drugs to assess their real safety.
Texto integral

Sobre autores
Olga Levchenkova
Smolensk State Medical University
Autor responsável pela correspondência
Email: levchenkova-o@yandex.ru
ORCID ID: 0000-0002-9595-6982
Dr.Sci. (Med.), Associate Professor of the Pharmacology Department
Rússia, SmolenskVasiliy Novikov
Smolensk State Medical University
Email: novikov.farm@yandex.ru
ORCID ID: 0000-0002-0953-7993
Dr.Sci. (Med.), Professor, Head of the Pharmacology Department
Rússia, SmolenskViktoriya Vorobyova
St. Petersburg State University
Email: v.v.vorobeva@mail.ru
ORCID ID: 0000-0001-6257-7129
Dr.Sci. (Med.), Professor of the Pharmacy Department
Rússia, St. PetersburgSergey Kozlov
Smolensk State Medical University
Email: Sergey.Kozlov@antibiotic.ru
Dr.Sci. (Med.), Professor, Head of the Clinical Pharmacology Department
Rússia, SmolenskBibliografia
- Semenza G.L. Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations. Annu. Rev. Med. 2023;74:307–19. doi: 10.1146/annurev-med-042921-102602.
- Novikov V.E., Levchenkova O.S. Pharmacological Regulation Possibilities of HIF for Its’ Mediated Pathologies in Clinical Practice. Ann. Rus. Acad. Med. Sci. 2024;79(3):261–70 (In Russ.) doi: 10.15690/vramn17946.
- Mikhailova N.A. Roxadustat: treatment of anemia and additional clinical effects (literature review). Clin. Nephrol. 2024;2;68–82 (In Russ.) doi: 10.18565/nephrology.2024.2.68-82.
- Novikov V.E., Levchenkova O.S. Inducers of the regulatory factor to hypoxia adaptation. I.P. Pavlov Rus. Med. Biol. Herald. 2014;2:133–43 (In Russ.)
- Semenza G.L. Hypoxia-inducible factors: roles in cardiovascular disease progression, prevention, and treatment. Cardiovasc. Res. 2023;119(2):371–80. doi: 10.1093/cvr/cvac089.
- Barratt J., Dellanna F., Portoles J., et al. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv. Ther. 2023;40(4):1546–59. doi: 10.1007/s12325-023-02433-0.
- Chen D., Niu Y., Liu F., et al. Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. Front. Pharmacol. 2023;14:1163908. doi: 10.3389/fphar.2023.1163908.
- Chen H., Cheng Q., Wang J., et al. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients. J. Clin. Pharm. Ther. 2021;46(4):999–1009. doi: 10.1111/jcpt.13385.
- Kang Yi., Zhou M., Jin Q., et al. The efficacy and safety of molidustat for anemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis. Heliyon. 2024;10:e30621. doi: 10.1016/j.heliyon.2024.e30621.
- Chen J., Shou X., Xu Y., et al. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. Aging (Albany NY). 2023;15(6):2237–74. doi: 10.18632/aging.204611.
- Huang Q., You M., Huang W., et al. Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis. Front. Pharmacol. 2023;14:1050412. doi: 10.3389/fphar.2023.1050412.
- Chou Y.H., Pan S.Y., Lin S.L. Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant? Kidney Res. Clin. Pract. 2023;42(1):27–38. doi: 10.23876/j.krcp.22.118.
- Clinical recommendations. Anemia in chronic kidney disease. 2024:34 (In Russ.)
- Shutov E.V. Controversial Issues of Anemia Treatment in Patients with CKD. New Possibilities. Effekt. Farmakoter. 2023;19(2):6–11 (In Russ.) doi: 10.33978/2307-3586-2023-19-2-6-11.
- Ogawa C., Tsuchiya K., Maeda K. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism. Int. J. Mol. Sci. 2023;24(3):3037. doi: 10.3390/ijms24033037.
- Gul K., Zaman N., Azam S.S. Roxadustat and its failure: A comparative dynamic study. J. Mol. Graph. Model. 2023;120:108422. doi: 10.1016/j.jmgm.2023.108422.
- Ren S., Zhao Y., Wu J., et al. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis. Front. Pharmacol. 2024;15:1406588. doi: 10.3389/fphar.2024.1406588.
- Yang J., Xing J., Zhu X., et al. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis stimulating agents on iron metabolism in non-dialysisdependent anemic patients with CKD: A network metaanalysis. Front. Endocrinol. (Lausanne). 2023;14:1131516. Doi: https://doi.org/10.3389/fendo.2023.1131516.
- Sackeyfio A., Lopes R.D., Kovesdy C.P., et al. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations. Clin. Kidney J. 2023;17(1):sfad298. doi: 10.1093/ckj/sfad298.
- Imai E., Imai A. The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia. Clin. Exp. Nephrol. 2024;28(11):1090–1096. doi: 10.1007/s10157-024-02511-9.
- Locatelli F., Del Vecchio L., Esposito C., et al. Collaborative Study Group on the Conservative Treatment of CKD of the Italian Society of Nephrology; Minutolo R. Consensus commentary and position of the Italian Society of Nephrology on KDIGO controversies conference on novel anemia therapies in chronic kidney disease. J. Nephrol. 2024;37(3):753–67. doi: 10.1007/s40620-024-01937-4.
- Ku E., Del Vecchio L., Eckardt K.U., et al. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023;104(4):655–80. doi: 10.1016/j.kint.2023.05.009.
- Stoumpos S., Crowe K., Sarafidis P., et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrol. Dial. Transplant. 2024;39(10):1710–30. doi: 10.1093/ndt/gfae075.
- Macdougall I.C. Anaemia in CKD-treatment standard. Nephrol. Dial. Transplant. 2024;39(5):770–7. doi: 10.1093/ndt/gfad250.
- Georgy M., Salhiyyah K., Yacoub M.H., Chester A.H. Role of hypoxia inducible factor HIF-1α in heart valves. Glob. Cardiol. Sci. Pract. 2023;2023(2):e202309. doi: 10.21542/gcsp.2023.9.
- Negri A.L. Role of prolyl hydroxylase/HIF-1 signaling in vascular calcification. Clin. Kidney J. 2022;16(2):205–9. doi: 10.1093/ckj/sfac224.
- Takahashi A. Zinc Supplementation Enhances the Hematopoietic Activity of Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors. Nutrients. 2024;16(4):520. doi: 10.3390/nu16040520.
- Li Q.Y., Xiong Q.W., Yao X., et al. Roxadustat: Do we know all the answers? Biomol. Biomed. 2023;23(3):354–63. doi: 10.17305/bb.2022.8437.
- Bartnicki P. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease. Biomedicines. 2024;12(8):1884. doi: 10.3390/biomedicines12081884.
- Zhou Q., Mao M., Li J., Deng F. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Ren. Fail. 2023;45(1):2195011. doi: 10.1080/0886022X.2023.2195011.
- Zhang W., Li Y., Wang J.G. Hypertension Induced by Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Treating Anemia in Patients With Chronic Kidney Disease: A Mini-Review. J. Clin. Hypertens. (Greenwich). 2024;26(12):1375–83. doi: 10.1111/jch.14924.
- He J., Jia Z., Zhang A., Bai M. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns. Pediatr. Nephrol. 2024;39(1):37–48. doi: 10.1007/s00467-023-06031-8.
- Johnson H.N., Prasad-Reddy L. Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease. Ann. Pharmacother. 2025;59(1):71–80. doi: 10.1177/10600280241241563.
- Ariyoshi N., Higashijima F., Wakuta M., et al. Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report. Case Rep. Ophthalmol. 2024;15(1):256–64. doi: 10.1159/000537913.
- Kita S., Okuyama H., Kondo T., et al. Low cholesterol levels are good markers for central hypothyroidism in case with dialysis using roxadustat. Clin. Case Rep. 2024;12(9):e9400. doi: 10.1002/ccr3.9400.
- Hirota K. HIF-α ProlylHydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review. Biomedicines. 2021;9:468. doi: 10.3390/biomedicines9050468.
- Kouki Y., Okada N., Saga K., et al. Disproportionality Analysis on Hypothyroidism With Roxadustat Using the Japanese Adverse Drug Event Database. J. Clin. Pharmacol. 2023;63(10):1141–6. doi: 10.1002/jcph.2300.
- Nakano Y., Mitsuboshi S., Tada K., et al. Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis. J. Pharm. Health. Care Sci. 2024;10:30. doi: 10.1186/s40780-024-00351-z.
- Kao T.W., Bai G.H., Wang T.L., et al. Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. J. Exp. Clin. Cancer Res. 2023;42:171. doi: 10.1186/s13046-023-02724-y.
- Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. Eur. J. Pharmacol. 2021;912:174583. doi: 10.1016/j.ejphar.2021.174583.
- Adams D.F., Watkins M.S., Durette L., et al. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor. Toxicol. Pathol. 2020;48(2):362–78. doi: 10.1177/0192623319880445.
- Kachamakova-Trojanowska N., Podkalicka P., Bogacz T., et al. HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo. Biochem. Pharmacol. 2020;175:113922. doi: 10.1016/j.bcp.2020.113922.
- Jacquemin C., El Orch W., Diaz O., et al. Pharmacological induction of the hypoxia response pathway in Huh7 hepatoma cells limits proliferation but increases resilience under metabolic stress. Cell. Mol. Life Sci. 2024;81(1):320. doi: 10.1007/s00018-024-05361-6.
- Lee S.H., Golinska M., Griffiths J.R. HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells. Cells. 2021;10(9):2371. doi: 10.3390/cells10092371.
- Kong W., Wu X., Huang H. Response to “Roxadustat: More Than an Erythropoietic Agent?”. Kidney Int. Rep. 2024;10(1):276. doi: 10.1016/j.ekir.2024.10.020.
- Angeletti A., Cravedi P. Roxadustat: More Than an Erythropoietic Agent? Kidney Int. Rep. 2024;10(1):275. doi: 10.1016/j.ekir.2024.06.042.
- Lu S., Wu J., Jiang J., et al. Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. J. Clin. Oncol. 2025;43(2):143–53. doi: 10.1200/JCO.23.02742.
- Tan J., Chen L., Zhu R. Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation. J. Clin. Oncol. 2025;13:JCO2402305. doi: 10.1200/JCO-24-02305.
- Rodgers G.M., Gilreath J.A. Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation. J. Clin. Oncol. 2025;13:JCO2402610. doi: 10.1200/JCO-24-02610.
- Sonia S.N., George S., Shahi S.R., et al. An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients. Cureus. 2023;15(7):e42045. doi: 10.7759/cureus.42045.
- Pai S.M., Yamada H. Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent. Clin. Pharmacol. Drug Dev. 2024;13(1):111–6. doi: 10.1002/cpdd.1336.
- Ryasnyansky V.Yu., Shostka G.D., Anikonova L.I. Nephrogenic anemia in patients receiving renal replacement therapy, pathogenesis and resistance. Clin. Nephrol. 2024;1: 58–66 (In Russ.) doi: 10.18565/nephrology.2024.1.58-66.
- Kashiv P., Malde S., Dubey S., et al. A Case of Erythropoietin (EPO)-Induced Pure Red Cell Aplasia and Its Treatment Efficacy With Desidustat. Cureus. 2024;16(6):e62022. doi: 10.7759/cureus.62022.
- Krysanov I.S., Makarova E.V., ERmakova V.Yu., Kurkin D.V. Comparative pharmacoeconomic analysis of the use of epoetin alfa and roxadustat in combination with iron supplements in adult patients with anemia against the background of chronic kidney disease in the healthcare system of the Russian Federation. Clin. Nephrol. 2024;1;15–24 (In Russ.) doi: 10.18565/nephrology.2024.1.15-24.
- https://kdigo.org/wp-content/uploads/2024/11/KDIGO-2025-Anemia-in-CKD-Guideline_Public-Review-Draft_Nov42024.pdf
- Faivre A., de Seigneux S. The role of hypoxia in chronic kidney disease: a nuanced perspective. Curr. Opin. Nephrol. Hypertens. 2024;33(4):414–9. doi: 10.1097/MNH.0000000000000989.
- Packer M. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia. Am. J. Nephrol. 2024;55(2):255–9. doi: 10.1159/000531084.
- Nakanishi T., Kuragano T. Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia. Clin. Kidney J. 2024;17(3):sfae051. doi: 10.1093/ckj/sfae051.
- Zurlo G., Guo J., Takada M., et al. New Insights into Protein Hydroxylation and Its Important Role in Human Diseases. Biochim. Biophys. Acta. 2016;1866(2):208–20. doi: 10.1016/j.bbcan.2016.09.004.
- Odawara M., Nishi H., Nangaku M. A spotlight on using HIF-PH inhibitors in renal anemia. Expert Opin. Pharmacother. 2024;25(10):1291–9. doi: 10.1080/14656566.2024.2378903.
- Weir M.R. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. Am. J. Nephrol. 2021;52(6):450–66. doi: 10.1159/000516901.
Arquivos suplementares
